logo
welcome
CNBC

CNBC

Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold

CNBC
Summary
Nutrition label

87% Informative

Moderna posted a surprise profit for the third quarter , smashing Wall Street estimates.

It is the first quarter that includes sales of Moderna 's vaccine against respiratory syncytial virus.

The biotech company is slashing expenses, with a recently announced goal of achieving $1.1 billion in savings by 2027 .

Before year end , the company plans to file for approval of its experimental "next-generation" Covid vaccine.

VR Score

93

Informative language

96

Neutral language

69

Article tone

semi-formal

Language

English

Language complexity

53

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Source diversity

1

Affiliate links

no affiliate links